Your browser doesn't support javascript.
loading
Quality of palliative radiotherapy assessed using quality indicators: a multicenter survey†.
Saito, Tetsuo; Shikama, Naoto; Takahashi, Takeo; Nakamura, Naoki; Mori, Takashi; Nakajima, Kaori; Koizumi, Masahiko; Sekii, Shuhei; Ebara, Takeshi; Kiyohara, Hiroki; Higuchi, Keiko; Yorozu, Atsunori; Nishimura, Takeshi; Ejima, Yasuo; Harada, Hideyuki; Araki, Norio; Miwa, Misako; Yamada, Kazunari; Kawamoto, Terufumi; Imano, Nobuki; Heianna, Joichi; Nozaki, Miwako; Wada, Yuki; Ohkubo, Yu; Uchida, Nobue; Watanabe, Miho; Kosugi, Takashi; Miyazawa, Kazunari; Yasuda, Shigeo; Onishi, Hiroshi.
Afiliação
  • Saito T; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto-Shi, Kumamoto 861-4193, Japan.
  • Shikama N; Department of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Takahashi T; Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama 350-8550, Japan.
  • Nakamura N; Department of Radiation Oncology, St. Marianna University Hospital, 2-16-1 Sugao, Miyamae, Kawasaki-shi, Kanagawa 216-8511, Japan.
  • Mori T; Department of Radiation Oncology, Hokkaido University Hospital, Kita 14 Nishi 5, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
  • Nakajima K; Department of Radiology, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa-shi, Hokkaido 078-8510, Japan.
  • Koizumi M; Radiation Oncology Laboratory, Department of Medical Physics & Engineering, Graduate School of Medicine and Health Science, Osaka University, 1-7 Yamadaoka, Suita-shi, Osaka 565-0871, Japan.
  • Sekii S; Department of Radiation Oncology, Kita-Harima Medical Center, 926-250 Ichibacho, Ono-shi, Hyogo 675-1392, Japan.
  • Ebara T; Department of Radiation Oncology, Kyorin University, School of Medicine, 6-20-2 Shinkawa Mitaka-shi, Tokyo 181-8611, Japan.
  • Kiyohara H; Department of Radiation Oncology, Japanese Red Cross Maebashi Hospital, 389-1 Asakura-Machi, Maebashi-shi, Gunma 371-0811, Japan.
  • Higuchi K; Department of Radiation Oncology, Isesaki Municipal Hospital, 12-1 Tsunatorihon-machi, Isesaki-Shi, Gunma 372-0817, Japan.
  • Yorozu A; Department of Radiation Oncology, NHO Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan.
  • Nishimura T; Department of Radiation Oncology, Japanese Red Cross Society Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto-Shi, Kyoto 605-0981, Japan.
  • Ejima Y; Department of Radiology, Dokkyo Medical University, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293  Japan.
  • Harada H; Radiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
  • Araki N; Department of Radiation Oncology, NHO Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto-shi, Kyoto 612-8555, Japan.
  • Miwa M; Department of Radiation Oncology, Sendai Kousei Hospital, 1-20 Sutsumidori, Amemiya, Aoba-ku, Sendai-shi, Miyagi 981-0914, Japan.
  • Yamada K; Department of Radiation Oncology, Seirei Mikatahara General Hospital, 3453 Mikatahara, Chuo-ku, Hamamatsu-shi, Shizuoka 433-8558, Japan.
  • Kawamoto T; Department of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Imano N; Department of Radiation Oncology, Graduate School of Biomedical Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima-shi, Hiroshima 734-8551, Japan.
  • Heianna J; Department of Radiation Oncology, Nanbu Tokushukai Hospital, 171-1 Hokama, Yaese-cho, Shimajiri-gun, Okinawa 901-0493, Japan.
  • Nozaki M; Department of Radiation Oncology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya-shi, Saitama 343-8555, Japan.
  • Wada Y; Department of Radiology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita-shi, Akita 010-8543, Japan.
  • Ohkubo Y; Department of Radiation Oncology, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-shi, Nagano 385-0051, Japan.
  • Uchida N; Department of Radiation Oncology, Kawasaki Municipal Ida Hospital, 2-27-1 Ida, Nakahara-ku, Kawasaki,-shi, Kanagawa 211-0035, Japan.
  • Watanabe M; Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
  • Kosugi T; Department of Radiation Oncology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda-shi, Shizuoka 426-8677, Japan.
  • Miyazawa K; Department of Radiolgy, Showa General Hospital, 8-1-1 Hanakoganei, Kodaira-shi, Tokyo 187-8510, Japan.
  • Yasuda S; Department of Radiology, Chiba Rosai Hospital, 2-16 Tatsumidai-higashi, Ichihara-shi, Chiba 290-0003, Japan.
  • Onishi H; Department of Radiology, University of Yamanashi, 1110 Shimokato, Chuo-shi, Yamanashi 409-3898, Japan.
J Radiat Res ; 2024 Jun 26.
Article em En | MEDLINE | ID: mdl-38923425
ABSTRACT
We sought to identify potential evidence-practice gaps in palliative radiotherapy using quality indicators (QIs), previously developed using a modified Delphi method. Seven QIs were used to assess the quality of radiotherapy for bone metastases (BoM) and brain metastases (BrM). Compliance rate was calculated as the percentage of patients for whom recommended medical care was conducted. Random effects models were used to estimate the pooled compliance rates. Of the 39 invited radiation oncologists, 29 (74%) from 29 centers participated in the survey; 13 (45%) were academic and 16 (55%) were non-academic hospitals. For the QIs, except for BoM-4, the pooled compliance rates were higher than 80%; however, for at least some of the centers, the compliance rate was lower than these pooled rates. For BoM-4 regarding steroid use concurrent with radiotherapy for malignant spinal cord compression, the pooled compliance rate was as low as 32%. For BoM-1 regarding the choice of radiation schedule, the compliance rate was higher in academic hospitals than in non-academic hospitals (P = 0.021). For BrM-3 regarding the initiation of radiotherapy without delay, the compliance rate was lower in academic hospitals than in non-academic hospitals (P = 0.016). In conclusion, overall, compliance rates were high; however, for many QIs, practice remains to be improved in at least some centers. Steroids are infrequently used concurrently with radiotherapy for malignant spinal cord compression.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article